Bellicum Pharmaceuticals (BLCM) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a sell rating to a hold rating in a report published on Monday.

A number of other brokerages also recently issued reports on BLCM. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, July 25th. Citigroup reduced their price target on shares of Bellicum Pharmaceuticals from $22.00 to $19.00 and set a buy rating on the stock in a report on Thursday, August 9th. Finally, Cantor Fitzgerald set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the company a buy rating in a report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $14.17.

NASDAQ BLCM traded up $0.01 on Monday, reaching $4.11. The company had a trading volume of 10,092 shares, compared to its average volume of 739,123. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.24 and a current ratio of 10.24. The company has a market cap of $214.58 million, a P/E ratio of -1.43 and a beta of 0.55. Bellicum Pharmaceuticals has a 12 month low of $4.08 and a 12 month high of $10.66.



Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.05). The business had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.08 million. As a group, analysts forecast that Bellicum Pharmaceuticals will post -2.45 EPS for the current fiscal year.

In other news, CTO David M. Spencer sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $7.04, for a total value of $70,400.00. Following the sale, the chief technology officer now directly owns 89,939 shares in the company, valued at approximately $633,170.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 9.84% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC increased its holdings in shares of Bellicum Pharmaceuticals by 52.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 18,888 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 6,530 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Bellicum Pharmaceuticals by 161.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 10,466 shares during the last quarter. Swiss National Bank increased its holdings in shares of Bellicum Pharmaceuticals by 32.3% in the 2nd quarter. Swiss National Bank now owns 58,600 shares of the biopharmaceutical company’s stock worth $432,000 after buying an additional 14,300 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Bellicum Pharmaceuticals by 21.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,524 shares of the biopharmaceutical company’s stock worth $844,000 after buying an additional 22,335 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Bellicum Pharmaceuticals in the 1st quarter worth about $170,000. Hedge funds and other institutional investors own 59.26% of the company’s stock.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply